b'Discoveries are often simply ideas plus inspiration.Around the Fitzsimons Innovation Community campus, its these ideas and the people behind them that generate some of the most important healthcare innovations and breakthroughs in the country.CUTTING-EDGE DISCOVERIES IN ACTIONOur Fitzsimons Innovation Community members are working on world-changing developments in bioscience and healthcare, and theyre doing it in workspace customized to their projects.80+35% Companies ForgingFitzsimons Innovation Community companies presented at the 2022 Rocky Visionary Organizations Strategic Partnerships Mountain Life Sciences Investor & Partnering Conference in Vail, Colorado.Partnerships evolved from primarily research collaborations to deployment, 800+manufacturing, and accountingInnovation is Happening. Right Here. Employees partnerships as companies advanced their innovations. Fitzsimons Innovation Community has been upper GI sampling technique for children and adults. Coupling a partner of the Rocky Mountain Life Sciencessuch routine, yet localized, sampling capability with new molecular, genomic, and microbiome assays for screening, $25M+ Capital Raised Investor & Partnering Conference since itsmonitoring, and diagnostics would substantially enhance 61% Companies inception, recognizing the importance of this personalized medicine approaches. A wide variety of areas Companies attracted more Making Discoveries gathering to showcase groundbreaking research benefit including food allergy, metabolic syndrome, GERD, than $25 million in investments Major breakthrough discoveries and innovations in the region. Learn moregut microbiome, esophageal cancer, Eosinophilic Esophagitis, to advance R&D, acceleratein pharmaceuticals, cell and gene about the 2022 presenting companies from theand other conditions within the GI, nutrition, allergy, or commercialization, support clinical therapy, medical devices, molecularCommunity who share a passion for taking theirmicrobiome spaces.trials, and fine-tune technology. biology, and diagnostics. research to the next level to improve care, cureForesight Diagnosticsdiseases, and save lives.Foresight Diagnostics is a precision medicine company dedicated to improving the lives of cancer patients through 12+ Patents Ceria Therapeutics improved cancer detection methods. There are 1.2 million 91% Companies ThrivingCompanies received more thanCeria is developing a pipeline of drug products based oncases of cancer in the United States each year. Of the patients 12 patents for their innovations,Majority of companies reported a single active agent to treat inflammatory diseases withthat are treated, approximately half of them will experience a 50% increase over the prior year. either no change to workforce or severe morbidity such as non-healing wounds, acute lungrelapse, and more than 600,000 will die. Early detection of added employees.inflammation, and severe intestinal distress. The companyscancer and cancer recurrence saves lives and healthcare costs. core technology addresses these conditions with single- While there have been major advances in the use of liquid administration drug products that block the underlying causebiopsy assays to speed the diagnosis and detection of cancer, 16+ New Innovations to rapidly resolve each condition. Patient benefits include thecurrent methods perform poorly when disease burden is low. 92% Companies Satisfied prevention of long-term drug therapy, surgery, and even death. This means that in the early stages of cancer, when detection Companies introduced more than 16Companies appreciate access tois critical to improve survival, cancer can go undiagnosed, new innovations to the market, fromEnteroTrack leading to disease progression. The low limit of detection of pharmaceuticals to molecularresources, opportunities to interact,EnteroTrack develops simple-to-use, minimally invasiveexisting liquid biopsy assays also means that recurrence after biology to medical devices. proximity to research institutions,technologies to sample gastrointestinal (GI) mucosal contenttreatment is often not detected until the tumors are large and the value offered by Communitythat can be assayed for various biomarkers of disease. Thereenough to be visible with conventional imaging, at which point Fitzsimons Innovation Community Member Growththe disease is much more difficult to treat.Survey Responses (JanuaryDecember 2021) membership. is currently no inexpensive, non-endoscopic, non-invasive Continued on next page6Fitzsimons Innovation Community Annual Innovation Report 7'